From March 19, 1997 Federal Register.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Method of Treating Established Colitis Using Antibodies Against IL-12
AGENCY: National Institutes of Health, Public Health Service, DHHS
ACTION: Notice
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a) (1) (I), announces that the National Institutes of Health is contemplating the grant of a co-exclusive world-wide license to Genetics Institute, Inc., a Delaware corporation headquartered in Cambridge, Massachusetts, and Protein Design Labs, Inc., a Delaware corporation headquartered in Mountain View, California, to practice the inventions embodied in U.S. Patent Application 08/547,979 and corresponding foreign patent applications entitled "Method of Treating Established Colitis Using Antibodies Against IL-12" in the field of treatment of inflammatory bowel disease. These inventions are owned by the Government of the United States of America as represented by the Department of Health and Human Services.
The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
SUPPLEMENTARY INFORMATION: The patent application discloses a method of treating the established colitis of an inflammatory bowel disease by administering the antibodies against IL-12. A method for evaluating the effectiveness of the IL-12 antibodies in reducing the inflammatory response is also presented.
ADDRESS: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Jaconda Wagner, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7735 ext. 284; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before May 19, 1997 will be considered. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
__________
Published in the Federal Register on Wednesday, March 19, 1997 [62 FR 13162]